AMP2 for Orthopedic Repair

About Theradaptive

Theradaptive is a private, preclinical-stage biotech founded in 2015, leveraging a proprietary protein engineering platform to overcome a central challenge in regenerative medicine: the precise and sustained local delivery of therapeutics. By engineering proteins to bind with high affinity to specific materials, the company aims to enhance efficacy and reduce systemic side effects across a range of clinical applications, with a lead focus on spinal fusion and orthopedic repair. The technology has demonstrated superiority over standard of care in multiple preclinical studies conducted at leading institutions, positioning the company to potentially redefine therapeutic delivery in surgery and beyond.

Therapeutic Areas